Please login to the form below

Not currently logged in
Email:
Password:

Glybera

This page shows the latest Glybera news and features for those working in and with pharma, biotech and healthcare.

AZ makes gene therapy move with 4DMT alliance

AZ makes gene therapy move with 4DMT alliance

While enormously exciting gene therapy is still very much in its infancy, with just three commercial gene therapies approved in Europe and the US since UniQure’s Glybera made its debut

Latest news

More from news
Approximately 4 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Health on instalment Health on instalment

    Before being pulled from the European market for safety concerns and lack of uptake, pancreatic drug Glybera cost $1m a dose.

  • Rare diseases: meeting the challenge Rare diseases: meeting the challenge

    Glybera, the expensive gene therapy developed for a small subset of patients with the rare familial lipoprotein lipase deficiency (LPLD). ... The company’s chief executive Matthew Kapusta said simply: “Glybera’s usage has been extremely limited and

  • Pharma deals in April 2015 Pharma deals in April 2015

    Following Glybera's approval in Europe for lipoprotein lipase deficiency (LPLD), uniQure, the gene therapy pioneer has announced an exclusive strategic collaboration with Bristol Myers Squibb (BMS) for its lead candidate ... Glybera's $1m cost per

  • Anticipating the future in healthcare Anticipating the future in healthcare

    As a gene therapy, Glybera is injected through a one-time course of up to 60 consecutive intramuscular injections. ... The introduction of therapies such as Glybera and Holostem will have significant implications on the healthcare ecosystem.

  • Gathering pace: adaptive pathways Gathering pace: adaptive pathways

    need for changes to its licensing framework in the wake of the approval last year of UniQure's gene therapy Glybera (alipogene tiparvovec) for lipoprotein lipase deficiency. ... Glybera was eventually approved for a narrower group of patients than

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics